Cite
Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center
MLA
Carlo Aul, et al. “Eligibility for Clinical Trials Is Unsatisfactory for Patients with Myelodysplastic Syndromes, Even at a Tertiary Referral Center.” Leukemia Research, vol. 108, Feb. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....26a6a2a610f24ee84be03f4c9ca606b3&authtype=sso&custid=ns315887.
APA
Carlo Aul, Guido Kobbe, Jennifer Kaivers, Volker Runde, Judith Strapatsas, Thomas Schroeder, Josefine Stark, Aristoteles Giagounidis, Esther Schuler, Andrea Kündgen, Christina Rautenberg, Kathrin Nachtkamp, Corinna Strupp, Ulrich Germing, Rainer Haas, & Norbert Gattermann. (2021). Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center. Leukemia Research, 108.
Chicago
Carlo Aul, Guido Kobbe, Jennifer Kaivers, Volker Runde, Judith Strapatsas, Thomas Schroeder, Josefine Stark, et al. 2021. “Eligibility for Clinical Trials Is Unsatisfactory for Patients with Myelodysplastic Syndromes, Even at a Tertiary Referral Center.” Leukemia Research 108 (February). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....26a6a2a610f24ee84be03f4c9ca606b3&authtype=sso&custid=ns315887.